Preclinical biotech Stoke Therapeutics plans $86M IPO
An RNA-altering startup, led by some of the brains behind Biogen and Sarepta Therapeutics' blockbuster products, is hoping to raise $86 million in an IPO, the company disclosed Thursday.
Stoke Therapeutics Inc. is developing RNA-targeting treatments that it hopes can jumpstart protein production in a handful of genetic diseases like a rare form of epilepsy called Dravet's Syndrome. It is also exploring potential therapies for liver, central nervous system, eye and kidney diseases.
The preclinical…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Allison DeAngelis Source Type: news
More News: Biotechnology | Brain | Epilepsy | Genetics | Health Management | Liver | Urology & Nephrology